12 citations
,
February 1997 in “British Journal of Dermatology” The enzyme type 1 5α-reductase is more active in the hair follicle's lower part than in the skin's outer layer.
6 citations
,
May 2020 in “JAMA Ophthalmology” Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
July 2024 in “Biological and Pharmaceutical Bulletin” Licorice extract helps hair growth and may treat hair loss.
14 citations
,
February 2018 in “Psychoneuroendocrinology” Mice lacking steroid 5α-reductase 2 show less aggression and better impulse control.
137 citations
,
March 2006 in “Cns Drug Reviews” Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
9 citations
,
August 2000 in “Journal of Periodontal Research” Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.
1 citations
,
January 2019 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Minoxidil 2% is more effective for female hair loss, but botanicals have fewer side effects.
63 citations
,
November 1999 in “British journal of dermatology/British journal of dermatology, Supplement” Hair sensitivity to androgens is partly controlled by specific enzyme expressions in different hair areas.
41 citations
,
March 1998 in “Archives of Dermatological Research” The enzyme that changes testosterone to a stronger form is mostly found in the part of the hair follicle called the dermal papilla.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
1 citations
,
August 2002 in “Zeitschrift für Hautkrankheiten” Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.
80 citations
,
January 1995 in “The American Journal of Medicine” Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.
11 citations
,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
100 citations
,
September 2017 in “Molecular and Cellular Endocrinology” Male hormones and their receptors play a key role in hair loss and skin health, with potential new treatments being explored.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
93 citations
,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
57 citations
,
February 1983 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.
15 citations
,
January 1998 in “Journal of Clinical Periodontology” Finasteride helps treat hair loss by blocking enzyme activity.
11 citations
,
August 2020 in “Diabetes” Testosterone helps human pancreatic cells increase insulin release.
November 2020 in “TURKDERM” Hormonal treatments effectively manage acne in some women, especially with specific hormonal issues.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
21 citations
,
February 2017 in “International Journal of Women's Dermatology” Hormonal therapies help treat female hair loss, but results are slow and vary.
3 citations
,
March 2014 in “Turkderm” Hair loss in men can be slowed or reversed with treatments like minoxidil and finasteride, but it resumes if treatment stops. It may also indicate early heart disease and obesity.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
149 citations
,
January 2011 in “Nature reviews. Urology” Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.
57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
136 citations
,
January 2004 in “Neuroscience” Testosterone increases seizure risk through its conversion to specific neurosteroids.
48 citations
,
January 2000 in “Hormone Research in Paediatrics” Cytokines and neuropeptides are key in controlling androgen levels, affecting skin and hair conditions.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.